GlobeNewswire Clinical StudiesOriginal article
Century Therapeutics' CNTY-813 Demonstrates Continued Advancement Toward the Clinic Via Nonclinical Data Presented at EASD 2026
ConferenceCNTY-813Positive
AI Analysis
Summary
Century Therapeutics presented nonclinical data for CNTY-813, its iPSC-derived islet replacement therapy for type 1 diabetes, at EASD 2026, demonstrating scalable production, in vivo function, immune evasion, and progress toward clinical dosing.
Outcome Details
Nonclinical data presented at EASD 2026 demonstrating scalable production, in vivo function, immune evasion, and progress toward clinical dosing
Importance:5/10
Sentiment:
0.60
iPSC-derived therapyislet replacementtype 1 diabetesnonclinical dataEASD 2026immune evasion
Related Companies
Read the original article
Published by GlobeNewswire Clinical Studies on October 2, 2026 12:05 PM